Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lapuleucel-T
- Development stage
- Discontinued
- Lead developer
- Dendreon
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
- Administration
- Intravenous
01
Overview
Lapuleucel-T (APC8024, Neuvenge) is an investigational autologous cellular immunotherapy developed by Dendreon Corporation, designed to treat tumors that overexpress the HER-2/neu (ERBB2) receptor. The production process involves collecting a patient's peripheral blood mononuclear cells (PBMCs) via leukapheresis and culturing them ex vivo with BA7072, a recombinant fusion protein. This fusion protein consists of the intracellular and extracellular domains of HER-2/neu linked to granulocyte-macrophage colony-stimulating factor (GM-CSF), which serves to activate and direct antigen-presenting cells (APCs) against the target. Once re-infused into the patient, these activated cells are intended to stimulate a robust T-cell-mediated immune response against HER-2/neu-positive cancer cells. Although it reached Phase II clinical trials for indications such as metastatic breast, ovarian, and colorectal cancers, its development was discontinued.
- Brand names
- Neuvenge
- Other names
- lapuleucel-T
Beyond the preview
Go deeper on lapuleucel-T.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lapuleucel-T.